Back to Search
DAVID JACKMAN, M.D.
M.D.
Medical Oncology Physician
NPI: 1386622413IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
221928(MA)
Education
BOSTON UNIVERSITY SCHOOL OF MEDICINE
Class of 2000
Research & Publications (20)
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
PMID 19671843·Clin Cancer Res·2009
8-other
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
PMID 18543326·Cancer·2008
3-trial
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
PMID 17228019·J Clin Oncol·2007
3-trial
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
PMID 16983123·J Clin Oncol·2006
5-case
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
PMID 16818686·Clin Cancer Res·2006
8-other
Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.
PMID 16052436·Semin Respir Crit Care Med·2005
6-review
Does erlotinib improve symptoms in patients with lung cancer?
PMID 17262089·Nat Clin Pract Oncol·2007
8-other
Recurrent malignant peritoneal mesothelioma: radiological manifestations.
PMID 19319590·Abdom Imaging·2010
8-other
Treatment of peritoneal mesothelioma in pediatric patients.
PMID 18819151·Pediatr Blood Cancer·2009
8-other
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
PMID 18980991·Clin Cancer Res·2008
8-other
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
PMID 18981003·Clin Cancer Res·2008
8-other
Shark skeletal muscle tropomyosin is a phosphoprotein.
PMID 18763042·J Muscle Res Cell Motil·2008
7-preclinical
Some binding properties of Omp T digested muscle tropomyosin.
PMID 17805980·J Muscle Res Cell Motil·2007
7-preclinical
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
PMID 17671154·Clin Cancer Res·2007
6-review
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
PMID 16862573·Cancer·2006
8-other
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
PMID 15519009·J Am Coll Cardiol·2004
3-trial
Characterisation of the intact rainbow trout vitellogenin protein and analysis of its derived tryptic and cyanogen bromide peptides by matrix-assisted laser desorption/ionisation time-of-flight-mass spectrometry and electrospray ionisation quadrupole/time-of-flight mass spectrometry.
PMID 14624020·Eur J Mass Spectrom (Chichester)·2003
7-preclinical
Adrenal insufficiency during the late stage of polymicrobial sepsis.
PMID 11373430·Crit Care Med·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, DANA-FARBER CANCER INSTITUTE, ROOM 1234C
BOSTON, MA 02115 - Phone
- (617) 632-6646
Quick Facts
- NPI
- 1386622413
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 26
- Publications
- 20
Are you this provider?
Claim Your Profile